NCT06033274ClinicalTrials.gov
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment: the TRIPLACE Registry
Kurz gefasst
The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction…
Beobachtend800 Teilnehmende gesucht31 Studienzentren8 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT06033274Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 5 Tagen
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2023-09-13; recorded start 2023-10-05
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
- Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
- Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 112 other studies in this databaseCounted from the lead sponsor named in the record (Montefiore Medical Center)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: other.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Masking not stated in the record
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 21 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 800 participants (target), run at 31 sites, across 8 countries.
How this score is built
- Enrolment29/40
800 participants (target)
- Site count16/25
21 sites
- Country count12/15
7 countries
- Planned duration8/10
Planned over about 34 months
- Sponsor scale8/10
Montefiore Medical Center has led 112 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction disturbances necessitating permanent pacemaker implantation, and how such patients are managed. On this background, the TRIPLACE Registry - an investigator-initiated global multicenter registry - is aimed at better understanding the safety and efficacy of orthotopic TTVR.
Erkrankungen
- Tricuspid Regurgitation
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
| Stichprobenverfahren | NON_PROBABILITY_SAMPLE |
Studienpopulation
Patients undergoing orthotopic Transcatheter Tricuspid Valve Replacement for clinically significant tricuspid valve disease.
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Beobachtend |
|---|---|
| Phase | Im Registereintrag nicht angegeben |
| Zuteilung | Im Registereintrag nicht angegeben |
| Interventionsmodell | Im Registereintrag nicht angegeben |
| Primäres Ziel | Im Registereintrag nicht angegeben |
| Verblindung | Im Registereintrag nicht angegeben |
| Teilnahme | 800 Teilnehmende gesucht |
Sponsor und Mitwirkende
- Montefiore Medical Center Sponsor
- The Cleveland Clinic Mitwirkende
- University of Toronto Mitwirkende
- University Hospital, Bordeaux Mitwirkende
Studienarme und Interventionen
- Patients with Tricuspid Regurgitation undergoing Transcatheter Tricuspid Valve Replacement
Patients having clinically significant tricuspid regurgitation, defined according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease, requiring transcatheter tricuspid valve replacement
Interventionen
- Medizinprodukt Transcatheter Tricuspid Valve Replacement
All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
Endpunkte
Primärer Endpunkt
Freedom from device-related complications
Freedom from device-related complications will be determined by assessing the number of participants with procedural, peri-procedural and device-related complications
Zeitrahmen 30 days after the index procedure
Primärer Endpunkt
Reduction in Tricuspid Regurgitation Severity
Tricuspid Regurgitation measured by transthoracic echocardiography. Assessment of MI severity according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease. Tricuspid Regurgitation is measured by transthoracic echocardiography in accordance with current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease. Mean tricuspid regurgitation severity will be determined using the following scale: 0=none/trace; 1=mild; 2=moderate; 3=severe; 4=massive; 5=torrential. Change from baseline tricuspid regurgitation severity score 30 days after baseline will be assessed
Zeitrahmen 30 days after the index procedure
Sekundärer Endpunkt
Tricuspid Valve Reintervention
The number of participants who undergo tricuspid valve surgical and/or transcatheter reintervention will be summed and recorded
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
Permanent Pacemaker Implantation
The number of participants who have received a permanent pacemaker implantation will be recorded
Zeitrahmen 30 days after the index procedure
Sekundärer Endpunkt
Combined all-cause mortality or rehospitalization for congestive heart failure
The composite of mortality from any cause and participants re-hospitalized for acute decompensated congestive heart failure will be recorded
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
All-cause mortality
The number of deaths due to any cause will be recorded
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
Hospitalization for congestive heart failure
The number of participants who have been hospitalized with acute decompensated congestive heart failure will be recorded
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
The number of participants with New York Heart Association (NYHA) Stage III or IV heart failure
The number of participants who meet either NYHA III or NYHA IV classifications for heart failure will be recorded. NYHA Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest NYHA Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
Device Thrombosis
The number of participants who have been identified with device thrombosis will be recorded
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
Tricuspid Regurgitation Severity
Tricuspid Regurgitation is measured by transthoracic echocardiography. Assessment of MI severity will be conducted in accordance with current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease. Mean tricuspid regurgitation severity will be determined using the following scale: 0=none/trace; 1=mild; 2=moderate; 3=severe; 4=massive; 5=torrential. Higher mean scores are indicative of greater TR severity
Zeitrahmen 12 months after the index procedure
Sekundärer Endpunkt
Quality of Life - Kansas City Cardiomyopathy Questionnaire
Quality of Life is evaluated using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ has a 2-week recall period and includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score, which can be combined with the physical limitation domain to create a clinical summary score that mirrors the key concepts of the NYHA functional class. The symptom, physical limitations, social limitations, and quality of life domains are combined to create an overall summary score, which is the primary health status outcome All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life
Zeitrahmen 12 months after the index procedure
Daten
| Startdatum | 5. Oktober 2023 (tatsächlich) |
|---|---|
| Primärer Abschluss | 1. Dezember 2028 (geschätzt) |
| Abschluss | 1. Dezember 2028 (geschätzt) |
| Erstveröffentlichung | 13. September 2023 (tatsächlich) |
| Zuletzt aktualisiert | 15. September 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | September 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
30 Studienzentren rekrutieren
Canada
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Montréal Heart Institute (MHI) | Montreal | Quebec | Rekrutiert |
| Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada | Québec | Quebec | Rekrutiert |
| St Michael's Hospital, University of Toronto | Toronto | Ontario | Rekrutiert |
| St. Paul's Hospital | Vancouver | British Columbia | Rekrutiert |
Denmark
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Rigshospitalet, Copenhagen University Hospital | Copenhagen | Capital Region | Rekrutiert |
France
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Chu De Bordeaux - Haut-Lévêque Hospital | Bordeaux | Pessac | Rekrutiert |
| Centre Hospitalier Universitaire de Lille | Lille | Hauts-de-France | Rekrutiert |
| Hospital Center University De Lille (CHU Lille) | Lille | Hauts-de-France | Rekrutiert |
| Clinique Pasteur Toulouse | Toulouse | Haute-Garonne | Rekrutiert |
Germany
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Heart and Diabetes Centre, North Rhine-Westphalia (NRW), Ruhr-University | Bad Oeynhausen | Rekrutiert | |
| Heart Center Cologne, University of Cologne | Cologne | Rekrutiert | |
| University of Duisberg-Essen, West German Heart and Vascular Centre | Essen | North Rhine-Westphalia | Rekrutiert |
| Cardiovascular Center (CVC) Frankfurt, Division of Cardiology | Frankfurt am Main | Hesse | Rekrutiert |
| University Heart and Vascular Center, Department of Cardiology | Hamburg | Rekrutiert | |
| University Heart Center, Schleswig-Holstein University | Lübeck | Schleswig-Holstein | Rekrutiert |
| Medical Clinic and Polyclinic, University Hospital of Munich (LMU Klinikum) | Munich | Bavaria | Rekrutiert |
Italy
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Centro Cardiologico Monzino IRCCS | Milan | Lombardy | Rekrutiert |
| San Raffaele University Hospital | Milan | Lombardy | Rekrutiert |
Spain
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Hospital Clínico Universitario de Valladolid | Valladolid | Rekrutiert | |
| University Hospital Alvaro Cunqueiro (CHUVI) | Vigo | Pontevedra | Rekrutiert |
Switzerland
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| University Hospital Basel | Basel | Canton of Basel-City | Rekrutiert |
| HerzZentrum Hirslanden Zürich | Zurich | Rekrutiert |
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| The Christ Hospital | Cincinnati | Ohio | Rekrutiert |
| Cleveland Clinic | Cleveland | Ohio | Rekrutiert |
| Hackensack University Medical Center | Hackensack | New Jersey | Rekrutiert |
| Columbia University Irving Medical Center | New York | New York | Rekrutiert |
| Arizona Heart Hospital (Biltmore Cardiology) | Phoenix | Arizona | Rekrutiert |
| Oregon Health & Science University | Portland | Oregon | Nicht angegeben |
| Providence St. Vincent Medical Center | Portland | Oregon | Rekrutiert |
| Montefiore Medical Center | The Bronx | New York | Rekrutiert |
| Ascension Via Christi | Wichita | Kansas | Rekrutiert |
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 15. September 2026
Abschlussdatum nach hinten verschoben
Primary completion delayed 853 days
2026-08-012028-12-01
- 15. September 2026
Studienzentrum hinzugefügt
10 sites added (31 total)
2131